PMID- 23847084 OWN - NLM STAT- MEDLINE DCOM- 20131125 LR - 20231213 IS - 1521-0111 (Electronic) IS - 0026-895X (Print) IS - 0026-895X (Linking) VI - 84 IP - 4 DP - 2013 Oct TI - Brain-derived neurotrophic factor-mediated downregulation of brainstem K+-Cl- cotransporter and cell-type-specific GABA impairment for activation of descending pain facilitation. PG - 511-20 LID - 10.1124/mol.113.086496 [doi] AB - Chronic pain is thought to be partly caused by a loss of GABAergic inhibition and resultant neuronal hyperactivation in the central pain-modulating system, but the underlying mechanisms for pain-modulating neurons in the brain are unclear. In this study, we investigated the cellular mechanisms for activation of brainstem descending pain facilitation in rats under persistent pain conditions. In the nucleus raphe magnus (NRM), a critical relay in the brain's descending pain-modulating system, persistent inflammatory pain induced by complete Freund's adjuvant decreased the protein level of K(+)-Cl(-) cotransporter (KCC2) in both total and synaptosomal preparations. Persistent pain also shifted the equilibrium potential of GABAergic inhibitory postsynaptic current (EIPSC) to a more positive level and increased the firing of evoked action potentials selectively in mu-opioid receptor (MOR)-expressing NRM neurons, but not in MOR-lacking NRM neurons. Microinjection of brain-derived neurotrophic factor (BDNF) into the NRM inhibited the KCC2 protein level in the NRM, and both BDNF administration and KCC2 inhibition by furosemide mimicked the pain-induced effects on EIPSC and excitability in MOR-expressing neurons. Furthermore, inhibiting BDNF signaling by NRM infusion of tyrosine receptor kinase B-IgG or blocking KCC2 with furosemide prevented these pain effects in MOR-expressing neurons. These findings demonstrate a cellular mechanism by which the hyperactivity of NRM MOR-expressing neurons, presumably responsible for descending pain facilitation, contributes to pain sensitization through the signaling cascade of BDNF-KCC2-GABA impairment in the development of chronic pain. FAU - Zhang, Zhi AU - Zhang Z AD - Department of Anesthesiology and Pain Medicine, University of Texas, MD Anderson Cancer Center, Houston, Texas (Z.Z., W.W., Z.Z.P.); Department of Neurobiology, University of Science and Technology of China, Hefei, People's Republic of China (Z.Z., X.W.); and Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, Texas (Y.-G.L.). FAU - Wang, Xinxing AU - Wang X FAU - Wang, Wei AU - Wang W FAU - Lu, Yun-Gang AU - Lu YG FAU - Pan, Zhizhong Z AU - Pan ZZ LA - eng GR - R01 DA023069/DA/NIDA NIH HHS/United States GR - R01 DA027541/DA/NIDA NIH HHS/United States GR - DA023069/DA/NIDA NIH HHS/United States GR - DA027541/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20130711 PL - United States TA - Mol Pharmacol JT - Molecular pharmacology JID - 0035623 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Symporters) RN - 56-12-2 (gamma-Aminobutyric Acid) SB - IM MH - Animals MH - Animals, Newborn MH - Brain Stem/cytology/drug effects/metabolism MH - Brain-Derived Neurotrophic Factor/*administration & dosage/physiology MH - Down-Regulation/drug effects/*physiology MH - Male MH - Microinjections MH - Organ Culture Techniques MH - Pain/*metabolism MH - Raphe Nuclei/cytology/drug effects/*metabolism MH - Rats MH - Rats, Wistar MH - Symporters/antagonists & inhibitors/*metabolism MH - gamma-Aminobutyric Acid/*metabolism MH - K Cl- Cotransporters PMC - PMC3781381 EDAT- 2013/07/13 06:00 MHDA- 2013/12/16 06:00 PMCR- 2014/10/01 CRDT- 2013/07/13 06:00 PHST- 2013/07/13 06:00 [entrez] PHST- 2013/07/13 06:00 [pubmed] PHST- 2013/12/16 06:00 [medline] PHST- 2014/10/01 00:00 [pmc-release] AID - mol.113.086496 [pii] AID - MOL_086496 [pii] AID - 10.1124/mol.113.086496 [doi] PST - ppublish SO - Mol Pharmacol. 2013 Oct;84(4):511-20. doi: 10.1124/mol.113.086496. Epub 2013 Jul 11.